-
Breast cancer facts & figures
-
(
TrogdonJG
LiuX
Reeder-HayesKE
, et al. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women. Cancer
2020; 126: 4118–4125.32648979)
TrogdonJG
LiuX
Reeder-HayesKE
, et al. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women. Cancer
2020; 126: 4118–4125.32648979
TrogdonJG
LiuX
Reeder-HayesKE
, et al. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women. Cancer
2020; 126: 4118–4125.32648979,
TrogdonJG
LiuX
Reeder-HayesKE
, et al. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women. Cancer
2020; 126: 4118–4125.32648979
-
N.
Harbeck,
F.
Franke,
Rafael
Villanueva-Vázquez,
Yen-Shen
Lu,
D.
Tripathy,
L.
Chow,
G.
Babu,
Y.
Im,
D.
Chandiwana,
A.
Gaur,
B.
Lanoue,
Karen
Rodriguez-Lorenc,
A.
Bardia
(2020)
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
Therapeutic Advances in Medical Oncology, 12
-
Johannes
Ettl,
Ruben
Quek,
Kyung-Hun
Lee,
H.
Rugo,
S.
Hurvitz,
A.
Gonçalves,
L.
Fehrenbacher,
R.
Yerushalmi,
Lida
Mina,
M.
Martín,
Henri
Roché,
Y.
Im,
D.
Markova,
H.
Bhattacharyya,
Alison
Hannah,
W.
Eiermann,
J.
Blum,
J.
Litton
(2018)
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
Annals of Oncology, 29
-
(
European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 scoring manual, version 3, 2001, https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf (accessed 27 September 2021).)
European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 scoring manual, version 3, 2001, https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf (accessed 27 September 2021).
European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 scoring manual, version 3, 2001, https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf (accessed 27 September 2021).,
European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 scoring manual, version 3, 2001, https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf (accessed 27 September 2021).
-
A.
Mariotto,
Ruth
Etzioni,
M.
Hurlbert,
L.
Penberthy,
M.
Mayer
(2017)
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Cancer Epidemiology, Biomarkers & Prevention, 26
-
K.
Burnham,
David
Anderson
(2004)
Multimodel Inference
Sociological Methods & Research, 33
-
P.
Fobair,
S.
Stewart,
Subo
Chang,
C.
D'onofrio,
Priscilla
Banks,
J.
Bloom
(2006)
Body image and sexual problems in young women with breast cancer
Psycho‐Oncology, 15
-
(
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2017.)
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2017.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2017.,
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2017.
-
(
RugoHS
DierasV
GelmonKA
, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol
2018; 29: 888–894.29360932)
RugoHS
DierasV
GelmonKA
, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol
2018; 29: 888–894.29360932
RugoHS
DierasV
GelmonKA
, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol
2018; 29: 888–894.29360932,
RugoHS
DierasV
GelmonKA
, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol
2018; 29: 888–894.29360932
-
(
BardiaA
HurvitzS
. Targeted therapy for premenopausal women with HR(+), HER2(-) advanced breast cancer: focus on special considerations and latest advances. Clin Cancer Res
2018; 24: 5206–5218.29884743)
BardiaA
HurvitzS
. Targeted therapy for premenopausal women with HR(+), HER2(-) advanced breast cancer: focus on special considerations and latest advances. Clin Cancer Res
2018; 24: 5206–5218.29884743
BardiaA
HurvitzS
. Targeted therapy for premenopausal women with HR(+), HER2(-) advanced breast cancer: focus on special considerations and latest advances. Clin Cancer Res
2018; 24: 5206–5218.29884743,
BardiaA
HurvitzS
. Targeted therapy for premenopausal women with HR(+), HER2(-) advanced breast cancer: focus on special considerations and latest advances. Clin Cancer Res
2018; 24: 5206–5218.29884743
-
(
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593)
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593,
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593
-
(
HamerJ
McDonaldR
ZhangL
, et al. Quality of life (QoL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer
2017; 25: 409–419.27696078)
HamerJ
McDonaldR
ZhangL
, et al. Quality of life (QoL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer
2017; 25: 409–419.27696078
HamerJ
McDonaldR
ZhangL
, et al. Quality of life (QoL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer
2017; 25: 409–419.27696078,
HamerJ
McDonaldR
ZhangL
, et al. Quality of life (QoL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer
2017; 25: 409–419.27696078
-
M.
Wallwiener,
N.
Nabieva,
L.
Haeberle,
F.
Taran,
A.
Hartkopf,
B.
Volz,
F.
Overkamp,
A.
Brandl,
H.
Kolberg,
P.
Hadji,
H.
Tesch,
J.
Ettl,
M.
Lux,
D.
Lueftner,
E.
Belleville,
P.
Fasching,
W.
Janni,
M.
Beckmann,
P.
Wimberger,
C.
Hielscher,
T.
Fehm,
S.
Brucker,
D.
Wallwiener,
A.
Schneeweiss,
V.
Mueller
(2018)
Abstract P6-11-10: Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry
Cancer Research, 78
-
(
Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer, 2021, https://seer.cancer.gov/statfacts/html/breast.html (accessed 27 September 2021).)
Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer, 2021, https://seer.cancer.gov/statfacts/html/breast.html (accessed 27 September 2021).
Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer, 2021, https://seer.cancer.gov/statfacts/html/breast.html (accessed 27 September 2021).,
Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer, 2021, https://seer.cancer.gov/statfacts/html/breast.html (accessed 27 September 2021).
-
N.
Harbeck,
S.
Hurvitz,
A.
Bardia,
F.
Franke,
K.
Babu,
P.
Wheatley-Price,
Y.
Im,
K.
Altundağ,
A.
Ridolfi,
D.
Chandiwana,
B.
Lanoue,
L.
Menon,
D.
Tripathy
(2020)
Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer
Cancer Research, 80
-
(
OusmenA
ConroyT
GuilleminF
, et al. Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time. Health Qual Life Outcomes
2016; 14: 167.27914467)
OusmenA
ConroyT
GuilleminF
, et al. Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time. Health Qual Life Outcomes
2016; 14: 167.27914467
OusmenA
ConroyT
GuilleminF
, et al. Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time. Health Qual Life Outcomes
2016; 14: 167.27914467,
OusmenA
ConroyT
GuilleminF
, et al. Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time. Health Qual Life Outcomes
2016; 14: 167.27914467
-
Wilson
Sheridan,
T.
Scott,
S.
Caroline,
Zheng
Yvonne,
B.
Vanessa,
Voduc
David,
G.
Karen,
C.
Stephen
(2014)
Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Breast Cancer Research and Treatment, 147
-
H.
Rugo,
V.
Diéras,
K.
Gelmon,
R.
Finn,
D.
Slamon,
M.
Martín,
P.
Neven,
Y.
Shparyk,
A.
Mori,
D.
Lu,
H.
Bhattacharyya,
C.
Bartlett,
S.
Iyer,
S.
Johnston,
Johannes
Ettl,
N.
Harbeck
(2018)
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
Annals of Oncology, 29
-
M.
Reilly,
A.
Zbrozek,
E.
Dukes
(1993)
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
PharmacoEconomics, 4
-
(
American Cancer Society. Breast cancer facts & figures
2019-2020, 2018, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf (accessed 27 September 2021).)
American Cancer Society. Breast cancer facts & figures
2019-2020, 2018, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf (accessed 27 September 2021).
American Cancer Society. Breast cancer facts & figures
2019-2020, 2018, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf (accessed 27 September 2021).,
American Cancer Society. Breast cancer facts & figures
2019-2020, 2018, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf (accessed 27 September 2021).
-
G.
Shmueli
(2010)
To Explain or To Predict?
Indian School of Business Research Paper Series
-
V.
Müller,
N.
Nabieva,
L.
Häberle,
F.
Taran,
A.
Hartkopf,
B.
Volz,
F.
Overkamp,
A.
Brandl,
H.
Kolberg,
P.
Hadji,
H.
Tesch,
J.
Ettl,
M.
Lux,
D.
Lüftner,
E.
Belleville,
P.
Fasching,
W.
Janni,
M.
Beckmann,
P.
Wimberger,
C.
Hielscher,
T.
Fehm,
S.
Brucker,
D.
Wallwiener,
A.
Schneeweiss,
M.
Wallwiener
(2018)
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.
Breast, 37
-
D.
Tripathy,
S.
Im,
M.
Colleoni,
F.
Franke,
A.
Bardia,
N.
Harbeck,
S.
Hurvitz,
L.
Chow,
J.
Sohn,
K.
Lee,
S.
Campos-Gómez,
R.
Vázquez,
K.
Jung,
K.
Babu,
P.
Wheatley-Price,
M.
Laurentiis,
Y.
Im,
S.
Kuemmel,
N.
El-Saghir,
Mei-Ching
Liu,
G.
Carlson,
G.
Hughes,
I.
Díaz-Padilla,
C.
Germa,
S.
Hirawat,
Yen-Shen
Lu
(2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
The Lancet. Oncology, 19 7
-
H.
Azim,
A.
Partridge
(2014)
Biology of breast cancer in young women
Breast Cancer Research : BCR, 16
-
Jingmei
Li,
K.
Humphreys,
M.
Eriksson,
Huma
Dar,
Y.
Brandberg,
P.
Hall,
K.
Czene
(2016)
Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross‐sectional study
International Journal of Cancer, 139
-
(
ReillyMC
ZbrozekAS
DukesEM
. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics
1993; 4: 353–365.10146874)
ReillyMC
ZbrozekAS
DukesEM
. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics
1993; 4: 353–365.10146874
ReillyMC
ZbrozekAS
DukesEM
. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics
1993; 4: 353–365.10146874,
ReillyMC
ZbrozekAS
DukesEM
. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics
1993; 4: 353–365.10146874
-
(
AkaikeH
. Information theory and an extension of the maximum likelihood principle. In:
PetrovBN
CsakiF
(eds) Proceeding of the 2nd international symposium on information theory. Budapest: Akadémiai Kiadó, 1973, pp. 267–281.)
AkaikeH
. Information theory and an extension of the maximum likelihood principle. In:
PetrovBN
CsakiF
(eds) Proceeding of the 2nd international symposium on information theory. Budapest: Akadémiai Kiadó, 1973, pp. 267–281.
AkaikeH
. Information theory and an extension of the maximum likelihood principle. In:
PetrovBN
CsakiF
(eds) Proceeding of the 2nd international symposium on information theory. Budapest: Akadémiai Kiadó, 1973, pp. 267–281.,
AkaikeH
. Information theory and an extension of the maximum likelihood principle. In:
PetrovBN
CsakiF
(eds) Proceeding of the 2nd international symposium on information theory. Budapest: Akadémiai Kiadó, 1973, pp. 267–281.
-
(
FobairP
StewartSL
ChangS
, et al. Body image and sexual problems in young women with breast cancer. Psychooncology
2006; 15: 579–594.16287197)
FobairP
StewartSL
ChangS
, et al. Body image and sexual problems in young women with breast cancer. Psychooncology
2006; 15: 579–594.16287197
FobairP
StewartSL
ChangS
, et al. Body image and sexual problems in young women with breast cancer. Psychooncology
2006; 15: 579–594.16287197,
FobairP
StewartSL
ChangS
, et al. Body image and sexual problems in young women with breast cancer. Psychooncology
2006; 15: 579–594.16287197
-
B.
Johnston,
S.
Ebrahim,
A.
Carrasco-Labra,
T.
Furukawa,
D.
Patrick,
M.
Crawford,
B.
Hemmelgarn,
H.
Schunemann,
G.
Guyatt,
G.
Nesrallah
(2015)
Minimally important difference estimates and methods: a protocol
BMJ Open, 5
-
J.
Hamer,
R.
McDonald,
Liying
Zhang,
S.
Verma,
A.
Leahey,
C.
Ecclestone,
G.
Bedard,
N.
Pulenzas,
A.
Bhatia,
R.
Chow,
C.
DeAngelis,
J.
Ellis,
E.
Rakovitch,
Justin
Lee,
E.
Chow
(2017)
Quality of life (QOL) and symptom burden (SB) in patients with breast cancer
Supportive Care in Cancer, 25
-
(
JohnstonBC
EbrahimS
Carrasco-LabraA
, et al. Minimally important difference estimates and methods: a protocol. BMJ Open
2015; 5: e007953.)
JohnstonBC
EbrahimS
Carrasco-LabraA
, et al. Minimally important difference estimates and methods: a protocol. BMJ Open
2015; 5: e007953.
JohnstonBC
EbrahimS
Carrasco-LabraA
, et al. Minimally important difference estimates and methods: a protocol. BMJ Open
2015; 5: e007953.,
JohnstonBC
EbrahimS
Carrasco-LabraA
, et al. Minimally important difference estimates and methods: a protocol. BMJ Open
2015; 5: e007953.
-
Ahmad
Ousmen,
T.
Conroy,
F.
Guillemin,
M.
Velten,
D.
Jolly,
M.
Mercier,
S.
Causeret,
J.
Cuisenier,
O.
Graesslin,
Z.
Hamidou,
F.
Bonnetain,
A.
Anota
(2016)
Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time
Health and Quality of Life Outcomes, 14
-
(
YinW
HorblyukR
PerkinsJJ
, et al. Association between breast cancer disease progression and workplace productivity in the United States. J Occup Environ Med
2017; 59: 198–204.28166126)
YinW
HorblyukR
PerkinsJJ
, et al. Association between breast cancer disease progression and workplace productivity in the United States. J Occup Environ Med
2017; 59: 198–204.28166126
YinW
HorblyukR
PerkinsJJ
, et al. Association between breast cancer disease progression and workplace productivity in the United States. J Occup Environ Med
2017; 59: 198–204.28166126,
YinW
HorblyukR
PerkinsJJ
, et al. Association between breast cancer disease progression and workplace productivity in the United States. J Occup Environ Med
2017; 59: 198–204.28166126
-
(
TripathyD
BardiaA
SellersWR
. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res
2017; 23: 3251–3262.28351928)
TripathyD
BardiaA
SellersWR
. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res
2017; 23: 3251–3262.28351928
TripathyD
BardiaA
SellersWR
. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res
2017; 23: 3251–3262.28351928,
TripathyD
BardiaA
SellersWR
. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res
2017; 23: 3251–3262.28351928
-
D.
Osoba,
G.
Rodrigues,
J.
Myles,
B.
Zee,
J.
Pater
(1998)
Interpreting the significance of changes in health-related quality-of-life scores.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 1
-
Cancer stat facts: female breast cancer
-
(
ShmueliG
. To explain or to predict?
Stat Sci
2010; 25: 289–310.)
ShmueliG
. To explain or to predict?
Stat Sci
2010; 25: 289–310.
ShmueliG
. To explain or to predict?
Stat Sci
2010; 25: 289–310.,
ShmueliG
. To explain or to predict?
Stat Sci
2010; 25: 289–310.
-
(
AzimHAJr
PartridgeAH
. Biology of breast cancer in young women. Breast Cancer Res
2014; 16: 427.25436920)
AzimHAJr
PartridgeAH
. Biology of breast cancer in young women. Breast Cancer Res
2014; 16: 427.25436920
AzimHAJr
PartridgeAH
. Biology of breast cancer in young women. Breast Cancer Res
2014; 16: 427.25436920,
AzimHAJr
PartridgeAH
. Biology of breast cancer in young women. Breast Cancer Res
2014; 16: 427.25436920
-
Jammbe
Musoro,
C.
Coens,
F.
Fiteni,
Pogoda
Katarzyna,
F.
Cardoso,
N.
Russell,
M.
King,
K.
Cocks,
M.
Sprangers,
M.
Groenvold,
G.
Velikova,
H.
Flechtner,
A.
Bottomley
(2019)
Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer
JNCI Cancer Spectrum, 3
-
(
MariottoAB
EtzioniR
HurlbertM
, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev
2017; 26: 809–815.28522448)
MariottoAB
EtzioniR
HurlbertM
, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev
2017; 26: 809–815.28522448
MariottoAB
EtzioniR
HurlbertM
, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev
2017; 26: 809–815.28522448,
MariottoAB
EtzioniR
HurlbertM
, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev
2017; 26: 809–815.28522448
-
D.
Tripathy,
A.
Bardia,
W.
Sellers
(2017)
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
Clinical Cancer Research, 23
-
(
LiJ
HumphreysK
ErikssonM
, et al. Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: a cross-sectional study. Int J Cancer
2016; 139: 2415–2425.27486698)
LiJ
HumphreysK
ErikssonM
, et al. Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: a cross-sectional study. Int J Cancer
2016; 139: 2415–2425.27486698
LiJ
HumphreysK
ErikssonM
, et al. Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: a cross-sectional study. Int J Cancer
2016; 139: 2415–2425.27486698,
LiJ
HumphreysK
ErikssonM
, et al. Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: a cross-sectional study. Int J Cancer
2016; 139: 2415–2425.27486698
-
S.
Im,
Yen-Shen
Lu,
A.
Bardia,
N.
Harbeck,
M.
Colleoni,
F.
Franke,
L.
Chow,
J.
Sohn,
K.
Lee,
S.
Campos-Gómez,
Rafael
Villanueva-Vázquez,
K.
Jung,
A.
Chakravartty,
G.
Hughes,
I.
Gounaris,
Karen
Rodriguez-Lorenc,
T.
Taran,
S.
Hurvitz,
D.
Tripathy
(2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
The New England journal of medicine
-
(
OsobaD
RodriguesG
MylesJ
, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol
1998; 16: 139–144.9440735)
OsobaD
RodriguesG
MylesJ
, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol
1998; 16: 139–144.9440735
OsobaD
RodriguesG
MylesJ
, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol
1998; 16: 139–144.9440735,
OsobaD
RodriguesG
MylesJ
, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol
1998; 16: 139–144.9440735
-
Julia
Medina,
Ingrid
Trugilho,
Giovanna
Mendes,
Josiel
Silva,
Maria
Paiva,
Suzana
Aguiar,
L.
Thuler,
A.
Bergmann
(2019)
Advanced Clinical Stage at Diagnosis of Breast Cancer Is Associated with Poorer Health-Related Quality of Life: A Cross-Sectional Study.
European journal of breast health, 15 1
-
Wes
Yin,
R.
Horblyuk,
J.
Perkins,
S.
Sison,
Greg
Smith,
J.
Snider,
Yanyu
Wu,
T.
Philipson
(2017)
Association Between Breast Cancer Disease Progression and Workplace Productivity in the United States
Journal of Occupational and Environmental Medicine, 59
-
(
ImSA
LuYS
BardiaA
, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med
2019; 381: 307–316.31166679)
ImSA
LuYS
BardiaA
, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med
2019; 381: 307–316.31166679
ImSA
LuYS
BardiaA
, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med
2019; 381: 307–316.31166679,
ImSA
LuYS
BardiaA
, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med
2019; 381: 307–316.31166679
-
EORTC QLQ-C30 scoring manual, version 3
-
(
MullerV
NabievaN
HaberleL
, et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast
2018; 37: 154–160.29237546)
MullerV
NabievaN
HaberleL
, et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast
2018; 37: 154–160.29237546
MullerV
NabievaN
HaberleL
, et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast
2018; 37: 154–160.29237546,
MullerV
NabievaN
HaberleL
, et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast
2018; 37: 154–160.29237546
-
(
HarbeckN
HurvitzS
BardiaA
, et al. Abstract P1-19-06: patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer. Cancer Res
2020; 80: P1-19-06.)
HarbeckN
HurvitzS
BardiaA
, et al. Abstract P1-19-06: patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer. Cancer Res
2020; 80: P1-19-06.
HarbeckN
HurvitzS
BardiaA
, et al. Abstract P1-19-06: patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer. Cancer Res
2020; 80: P1-19-06.,
HarbeckN
HurvitzS
BardiaA
, et al. Abstract P1-19-06: patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer. Cancer Res
2020; 80: P1-19-06.
-
(
SheridanW
ScottT
CarolineS
, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Breast Cancer Res Treat
2014; 147: 617–629.25209005)
SheridanW
ScottT
CarolineS
, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Breast Cancer Res Treat
2014; 147: 617–629.25209005
SheridanW
ScottT
CarolineS
, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Breast Cancer Res Treat
2014; 147: 617–629.25209005,
SheridanW
ScottT
CarolineS
, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Breast Cancer Res Treat
2014; 147: 617–629.25209005
-
(
EttlJ
QuekRGW
LeeKH
, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol
2018; 29: 1939–1947.30124753)
EttlJ
QuekRGW
LeeKH
, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol
2018; 29: 1939–1947.30124753
EttlJ
QuekRGW
LeeKH
, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol
2018; 29: 1939–1947.30124753,
EttlJ
QuekRGW
LeeKH
, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol
2018; 29: 1939–1947.30124753
-
H.
Akaike
(1973)
Information Theory and an Extension of the Maximum Likelihood Principle
, 1
-
Multimodel inference: understanding AIC and BIC in model selection
-
R.
Team
(2014)
R: A language and environment for statistical computing.
MSOR connections, 1
-
F.
Bray,
J.
Ferlay,
I.
Soerjomataram,
R.
Siegel,
Lindsey
Torre,
A.
Jemal
(2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA: A Cancer Journal for Clinicians, 68
-
A.
Bardia,
S.
Hurvitz
(2018)
Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Clinical Cancer Research, 24
-
European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 scoring manual
-
(
MusoroJZ
CoensC
FiteniF
, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectr
2019; 3: pkz037.)
MusoroJZ
CoensC
FiteniF
, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectr
2019; 3: pkz037.
MusoroJZ
CoensC
FiteniF
, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectr
2019; 3: pkz037.,
MusoroJZ
CoensC
FiteniF
, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectr
2019; 3: pkz037.
-
(
De Mello Ramirez MedinaJ
De Araujo TrugilhoI
MendesGNB
, et al. Advanced clinical stage at diagnosis of breast cancer is associated with poorer health-related quality of life: a cross-sectional study. Eur J Breast Health
2019; 15: 26–31.30816366)
De Mello Ramirez MedinaJ
De Araujo TrugilhoI
MendesGNB
, et al. Advanced clinical stage at diagnosis of breast cancer is associated with poorer health-related quality of life: a cross-sectional study. Eur J Breast Health
2019; 15: 26–31.30816366
De Mello Ramirez MedinaJ
De Araujo TrugilhoI
MendesGNB
, et al. Advanced clinical stage at diagnosis of breast cancer is associated with poorer health-related quality of life: a cross-sectional study. Eur J Breast Health
2019; 15: 26–31.30816366,
De Mello Ramirez MedinaJ
De Araujo TrugilhoI
MendesGNB
, et al. Advanced clinical stage at diagnosis of breast cancer is associated with poorer health-related quality of life: a cross-sectional study. Eur J Breast Health
2019; 15: 26–31.30816366
-
J.
Trogdon,
Xuejun
Liu,
K.
Reeder-Hayes,
J.
Rotter,
D.
Ekwueme,
S.
Wheeler
(2020)
Productivity costs associated with metastatic breast cancer in younger, midlife, and older women.
Cancer
-
(
BurnhamKP
AndersonDR
. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res
2004; 33: 261–304.)
BurnhamKP
AndersonDR
. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res
2004; 33: 261–304.
BurnhamKP
AndersonDR
. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res
2004; 33: 261–304.,
BurnhamKP
AndersonDR
. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res
2004; 33: 261–304.
-
K.
Burnham,
David
Anderson
(2004)
Understanding AIC and BIC in Model Selection